Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University, Yonago, Tottori, Japan.
Chromosome Engineering Research Center, Tottori University, Yonago, Tottori, Japan.
PLoS One. 2018 Mar 5;13(3):e0193642. doi: 10.1371/journal.pone.0193642. eCollection 2018.
Mouse artificial chromosome (MAC) vectors have several advantages as gene delivery vectors, such as stable and independent maintenance in host cells without integration, transferability from donor cells to recipient cells via microcell-mediated chromosome transfer (MMCT), and the potential for loading a megabase-sized DNA fragment. Previously, a MAC containing a multi-integrase platform (MI-MAC) was developed to facilitate the transfer of multiple genes into desired cells. Although the MI system can theoretically hold five gene-loading vectors (GLVs), there are a limited number of drugs available for the selection of multiple-GLV integration. To overcome this issue, we attempted to knock out and reuse drug resistance genes (DRGs) using the CRISPR-Cas9 system. In this study, we developed new methods for multiple-GLV integration. As a proof of concept, we introduced five GLVs in the MI-MAC by these methods, in which each GLV contained a gene encoding a fluorescent or luminescent protein (EGFP, mCherry, BFP, Eluc, and Cluc). Genes of interest (GOI) on the MI-MAC were expressed stably and functionally without silencing in the host cells. Furthermore, the MI-MAC carrying five GLVs was transferred to other cells by MMCT, and the resultant recipient cells exhibited all five fluorescence/luminescence signals. Thus, the MI-MAC was successfully used as a multiple-GLV integration vector using the CRISPR-Cas9 system. The MI-MAC employing these methods may resolve bottlenecks in developing multiple-gene humanized models, multiple-gene monitoring models, disease models, reprogramming, and inducible gene expression systems.
鼠人工染色体(MAC)载体作为基因递送载体具有多个优势,如在宿主细胞中稳定且独立地维持而不整合,通过微细胞介导的染色体转移(MMCT)从供体细胞转移到受体细胞,以及加载兆碱基大小 DNA 片段的潜力。以前,开发了含有多整合酶平台(MI-MAC)的 MAC 以促进将多个基因转移到所需的细胞中。尽管 MI 系统理论上可以容纳五个基因加载载体(GLV),但可用于选择多个 GLV 整合的药物数量有限。为了克服这个问题,我们试图使用 CRISPR-Cas9 系统敲除和再利用耐药基因(DRG)。在这项研究中,我们开发了用于多 GLV 整合的新方法。作为概念验证,我们通过这些方法在 MI-MAC 中引入了五个 GLV,其中每个 GLV 都包含一个编码荧光或发光蛋白(EGFP、mCherry、BFP、Eluc 和 Cluc)的基因。MI-MAC 上的感兴趣基因(GOI)在宿主细胞中稳定且功能性地表达,而没有沉默。此外,通过 MMCT 将携带五个 GLV 的 MI-MAC 转移到其他细胞中,所得的受体细胞显示出所有五个荧光/发光信号。因此,成功地使用 CRISPR-Cas9 系统将 MI-MAC 用作多 GLV 整合载体。采用这些方法的 MI-MAC 可能会解决开发多基因人源化模型、多基因监测模型、疾病模型、重编程和诱导基因表达系统的瓶颈。